Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 41

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 41
---
 property
rights and protect our products. These legal means, however, afford only limited protection and may not completely protect our rights.

As of March 10, 2025, our exclusively owned patent portfolio includes
thirty-four (34) issued patents, of which eight (8) are U.S. patents and twenty-six (26) are foreign patents, with eighteen (18) of the
twenty-six (26) foreign patents being nationally validated in certain European extension/validation states). We cannot assure you that
our intellectual property position will not be challenged or that all patents for which we have applied will be granted. The validity
and breadth of claims in patents involves complex legal and factual questions and, therefore, may be highly uncertain. Uncertainties and
risks that we face include the following:

| ● | our pending or future patent                                                                                               
 applications may not result in the issuance of patents;                                                                    |
| ● | the scope of any existing                                                                                                  
 or future patent protection may not exclude competitors or provide competitive advantages to us;                           |
| ● | our patents may not be                                                                                                     
 held valid or enforceable if subsequently challenged;                                                                      |
| ● | other parties may claim                                                                                                    
 that our products and designs infringe the proprietary rights of others—even if we are successful in defending our patents 
 and proprietary rights, the cost of such litigation may adversely affect our business; and                                 |
| ● | other parties may develop                                                                                                  
 similar products, duplicate our products, or design around our patents.                                                    |

The patent prosecution process
is expensive and time-consuming, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent
applications at a reasonable cost or in a timely manner, or in all jurisdictions. We may choose not to seek patent protection for certain
innovations and may choose not to pursue patent protection in certain jurisdictions, and under the laws of certain jurisdictions, patents
or other intellectual property rights may be unavailable or limited in scope. It is also possible that we will fail to identify patentable
aspects of our developments before it is too late to obtain patent protection.

In addition, the laws of
foreign jurisdictions may not protect our rights to the same extent as the laws of the United States. For example, most countries outside
of the United States do not allow patents for methods of treating the human body. This may preclude us from obtaining method patents
outside of the United States having similar scope to those we have obtained or may obtain in the